Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AssigneeIntellikine LLC
InventorsPingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
Life of this patent
Estimating the term…
Abstract
Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
Claims170
A method of inhibiting a phosphatidyl inositol-3 kinase (PI3 kinase) in a subject, comprising administering to the subject an effective amount of a compound of Formula I-1:
- or a pharmaceutically acceptable salt thereof, wherein:
- B is a moiety of Formula II:
- wherein:
- Wc is aryl, heteroaryl, heterocycloalkyl, or cycloalkyl, and
- q is an integer of 0, 1, 2, 3, or 4;
- X is a bond or —(CH(R9))z—, and z is an integer of 1;
- Y is —N(R9)—;
- Wd is:
- R1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amido, alkoxycarbonyl, sulfonamido, halo, cyano, or nitro;
- R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heteroarylalkyl, alkoxy, amino, halo, cyano, hydroxy or nitro;
- R3 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, amido, amino, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy or nitro;
- and
- each instance of R9 is independently hydrogen, alkyl, or heterocycloalkyl.
A method of inhibiting a phosphatidyl inositol-3 kinase (PI3 kinase) in a subject suffering from a cancer, comprising administering to the subject an effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof,
- wherein the cancer is leukemia or lymphoma.
A method of inhibiting a phosphatidyl inositol-3 kinase (PI3kinase) in a subject suffering from a cancer, comprising administering to the subject an effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof,
- wherein the cancer is leukemia or lymphoma.
A method of inhibiting phosphatidyl inositol-3 kinase (PI3 kinase) in a subject suffering from an inflammatory disease, comprising administering to the subject an effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof,
- wherein the inflammatory disease is asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, psoriasis, lupus erythematosus, graft versus host disease, inflammatory bowel disease, eczema, scleroderma, Crohn's disease, atherosclerosis, encephalomyelitis, or multiple sclerosis.
A method of inhibiting a phosphatidyl inositol-3 kinase (PI3 kinase) in a subject:
- suffering from an inflammatory disease, comprising administering to the subject an effective amount of a compound having the following structures:
- or a pharmaceutically acceptable salt thereof,
- wherein the inflammatory disease is asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, psoriasis, lupus erythematosus, graft versus host disease, inflammatory bowel disease, eczema, scleroderma, Crohn's disease, atherosclerosis, encephalomyelitis, or multiple sclerosis.
A method of inhibiting a phosphatidyl inositol-3 kinase(PI3 kinase) in a subject suffering from a respiratory disease, comprising administering to the subject an effective amount of a compound having the following structure:
- or a pharmaceutically salt thereof,
- wherein the respiratory disease is asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, or bronchiectasis.
A method of inhibiting a phosphatidyl inositol-3 kinase (PI3 kinase) in a subject suffering from a respiratory disease, comprising administering to the subject an effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof,
- wherein the respiratory disease is asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, or bronchiectasis.
Dependencies are inferred from the claim text.